References
- Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11(3), 343–349 (2011).
- Godman B, Bennie M, Baumgärtel C et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia: Health Economics and Therapeutic Pathways 13(3S), 5–20 (2012).
- Godman B, Paterson K, Malmström RE et al. Improving the managed entry of new drugs: sharing experiences across Europe. Expert Rev. Pharmacoecon. Outcomes Res. 12(4), 439–441 (2012).
- Garattini S. Time to revisit the orphan drug law. Eur. J. Clin. Pharmacol. 68(2), 113 (2012).
- Brkicic LS, Godman B, Voncina L, Sovic S, Relja M. Initiatives to improve prescribing efficiency for drugs to treat Parkinson’s disease in Croatia: influence and future directions. Expert Rev. Pharmacoecon. Outcomes Res. 12(3), 373–384 (2012).
- Kalaba M, Godman B, Vuksanovic A et al. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? J. Compar. Effect. Res. 1(6), 539–549 (2012).
- Gustafsson LL, Wettermark B, Godman B et al.; Regional Drug Expert Consortium. The ‘wise list’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108(4), 224–233 (2011).